SCHEMBL23927464

SCHEMBL23927464

CCOC(=O)c1nnc(Cc2cc(F)ccc2F)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MMP2 P08253 2/20 0.45
MMP12 P39900 2/20 0.45
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927468 0.90 TSHR (0.43) TSHRKMT2AHPGDMEN1MAPK1
SCHEMBL30091646 0.89 ALOX15 (0.45) TSHRHPGDMAPK1SMN1; SMN2ALDH1A1
SCHEMBL30091676 0.89 KMT2A (0.38) TSHRKMT2AHPGDMEN1MAPK1
SCHEMBL23927454 0.89 ALOX15 (0.45) TSHRHPGDMAPK1SMN1; SMN2ALDH1A1
SCHEMBL23927442 0.89 KMT2A (0.38) TSHRKMT2AHPGDMEN1MAPK1
SCHEMBL23927496 0.85 KDM4E (0.40) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL23927502 0.85 MMP2 (0.41) TSHRKMT2AHPGDMEN1MAPK1
SCHEMBL23927450 0.85 RIPK1 (0.37) TSHRKMT2AHPGDMEN1MAPK1
SCHEMBL23927475 0.84 PDE3B (0.42) KMT2AHPGDNPSR1KDM4ESMN1; SMN2
SCHEMBL23927507 0.84 HPGD (0.40) TSHRKMT2AHPGDMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 TSHR 2607/4885KMT2A 2048/4885HPGD 2673/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 TSHR 2607/4885KMT2A 2048/4885HPGD 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.